Alphyn Biologics, a clinical-stage dermatology company pioneering first-in-class Multi-Target Therapeutics, has closed a $25 million, twice-oversubscribed Series B financing round.
The funds will support a Phase 2b global clinical trial of Alphyn’s lead drug candidate, Zabalafin Hydrogel, for atopic dermatitis (AD), launch a second Phase 2 program for molluscum contagiosum virus (MCV), and expand the company’s drug raw material supply.
The financing was led by QCA Investment Group and included existing backers Angel Physicians Fund, Serial Stage Venture Partners, a corporate fund, and several new investors.
“We are incredibly grateful for the support of our current and new investors. This financing reflects their confidence in our Multi-Target Therapeutic Drug Platform and our unique and highly differentiated drug candidates for atopic dermatitis and the molluscum contagiosum virus,” said Alphyn CEO Neal Koller.
“We are well-positioned to rapidly advance Zabalafin Hydrogel towards our next key milestones—two pivotal Phase 3 trials—while broadening our pipeline of breakthrough therapies for skin diseases.”
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD—inflammation, itch, bacteria, and dry skin—and MCV, addressing the virus, itch, inflammation, molluscum rash, and bacterial infections with associated pain.
Unlike current treatments, which target only one disease driver, Zabalafin Hydrogel aims for sustained management and long-term control. For MCV, it could become the first direct antiviral that is safe, gentle, and effective, offering a real treatment option for millions of children, unlike current blistering, painful therapeutics.
“Alphyn is breaking new ground with a first-in-class, natural topical therapeutic that is expected to directly addresses all of AD’s problems and have the potential for long-term, continuous use,” said Tony Shipley, chairman of Alphyn’s lead investor, QCA Investment Group.
“With an experienced leadership team and their continued strong execution, Alphyn is poised to meet two tremendous market needs and bring patients a highly innovative new therapy for AD and MCV.”
